Skip to content
drillr.ai
Sign up

002603.SZ

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 15.37
−1.16%
Ask drillr

  • Oct 22, 2026, 08:40 UTC

    China’s National Medical Products Administration accepted Beijing Yiling Pharmaceutical’s clinical-trial application for the traditional Chinese medicine Jian Gu Guan Jie Granules.

    Source:

  • Oct 20, 2026, 08:02 UTC

    China’s National Medical Products Administration approved clinical trials for Yiling Pharmaceutical’s LB220-D08 sustained-release tablets for atypical hemolytic uremic syndrome.

    Source:

  • Sep 28, 2026, 11:36 UTC

    Yiling Pharmaceutical partnered with Taobao Flash Purchase to hold a public-welfare event in Putuo District, Shanghai, providing Lianhua respiratory health products and health guidance to delivery riders and couriers.

    Source:

  • Aug 31, 2026, 23:17 UTC

    China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.

    Source:

  • Aug 28, 2026, 09:37 UTC

    Yiling Pharmaceutical announced its first-half 2026 results with revenue of 4.075 billion yuan, net profit of 757 million yuan, and no dividend distribution.

    Source:

  • Aug 12, 2026, 08:55 UTC

    Yiling Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of its self-developed Class 1 chemical new drug LB220-D08 sustained-release tablets, a complement inhibitor targeting Factor B for atypical hemolytic uremic syndrome.

    Source:

  • Jul 16, 2026, 04:14 UTC

    Shijiazhuang Yiling Pharmaceutical (02005.HK) obtained a drug production registration approval from the National Medical Products Administration for fenofibrate choline sustained-release capsules, classified as Category 4 chemical drugs and deemed to have passed consistency evaluation.

    Source:

  • Jul 10, 2026, 09:05 UTC

    Shijiazhuang Yiling Pharmaceutical (02005) received drug production registration approvals from the National Medical Products Administration for two drugs, propylthiouracil tablets (50mg) and calcium gluconate sodium chloride injection (50ml:1g/0.3375g), both deemed to have passed consistency evaluation.

    Source:

  • Jul 10, 2026, 04:08 UTC

    Shijiazhuang Yiling Pharmaceutical (02005.HK) announced that 95 of its drug varieties have been included in China's National Essential Drugs List (2026 edition), which will take effect on September 1.

    Source:

  • Jul 6, 2026, 09:07 UTC

    Yiling Pharmaceutical's wholly-owned subsidiary Wan Yang Hengshui Pharmaceutical received approval from the National Medical Products Administration for its irbesartan active pharmaceutical ingredient listing application.

    Source:

  • Jul 2, 2026, 00:07 UTC

    Shijiazhuang Yiling Pharmaceutical (Shijiazhuang Yiling Pharmaceutical) obtained a drug production registration certificate for Methocarbamol Tablets (0.5g) from the National Medical Products Administration (NMPA), becoming the first domestic company to receive such approval.

    Source: